The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli ...

The best subscription boxes for men have three things in common: carefully selected products, some level of user customization and a good value for the price. Plus, sometimes you find an ...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The cost-effectiveness agency for England ...

After hours: October 15 at 5:46 PM EDT Loading Chart for BOX ...

Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide's superiority over other GLP-1 agonists for ...